Literature DB >> 33285433

Advantages of preoperative localization and surgical resection of metastatic axillary lymph nodes using magnetic seeds after neoadjuvant chemotherapy in breast cancer.

Antonio Mariscal Martínez1, Irene Vives Roselló2, Angela Salazar Gómez3, Alessandro Catanese3, Mariola Pérez Molina3, Montserrat Solà Suarez4, Iciar Pascual Miguel5, Lidia Blay Aulina5, Cristian Ríos Gozálvez6, José Francisco Julián Ibáñez5, Paula Rodríguez Martínez7, Sergio Martínez Román6, Mireia Margelí Vila8, Miguel Angel Luna Tomás6.   

Abstract

PURPOSE: To assess the safety and effectiveness of magnetic seeds in preoperative localization and surgical dissection of metastatic axillary lymph nodes (LN+) in breast cancer patients with axillary involvement, after neoadjuvant chemotherapy (NAC). In addition, to assess the impact of targeted axillary dissection (TAD) in reducing the rate of false negatives (FN) in sentinel lymph node biopsy (SLNB).
MATERIALS AND METHODS: A cross-sectional prospective cohort study was conducted from April 2017 to September 2019, including breast cancer patients with axillary lymph node involvement treated with NAC. Prior to NAC, the LN+ were marked by ultrasound-guided clip insertion. After NAC, a magnetic seed (Magseed®) was inserted in the clip-marked lymph node (MLN). During surgery, the MLN was located and removed with the aid of a magnetic detection probe (Sentimag®) and the sentinel lymph node was removed. Axillary lymph node dissection (ALND) was used to determine the rate of FN for SLNB alone and the combination of SLNB and MLN dissection, called TAD.
RESULTS: The study included 29 patients (mean age, 55; range, 30-78 years). Selective preoperative localization and surgical dissection were successful for all 30 MLNs (100%). The MLN corresponded to the SLN in 50% of cases. After ALND, there were 21.4% (3/14) FN with SLNB alone and 5.9% (1/17) with TAD.
CONCLUSIONS: Following NAC, selective surgical removal of MLN by preoperative localization using magnetic seeds is a safe and effective procedure with a success rate of 100%. Adding TAD reduces the rate of FN associated with SLNB alone.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Magnetic seed; Marked axillary lymph nodes; Neoadjuvant chemotherapy; Sentinel lymph node biopsy

Year:  2020        PMID: 33285433     DOI: 10.1016/j.suronc.2020.11.013

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  5 in total

Review 1.  De-Escalating Axillary Surgery in Node-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy.

Authors:  Sabine R de Wild; Janine M Simons; Marie-Jeanne T F D Vrancken Peeters; Marjolein L Smidt; Linetta B Koppert
Journal:  Breast Care (Basel)       Date:  2021-08-17       Impact factor: 2.860

2.  Improved false-negative rates using a novel patient selection flowchart in initially biopsy-proven node-positive breast cancer undergoing blue-dye alone guided sentinel lymph node biopsy after neoadjuvant chemotherapy.

Authors:  Minyan Chen; Shengmei Li; Meng Huang; Jingjing Guo; Xuan Huang; Wenhui Guo; Lili Chen; Yuxiang Lin; Lisa Jacobs; Chuan Wang; Fangmeng Fu
Journal:  Breast Cancer Res Treat       Date:  2022-09-13       Impact factor: 4.624

3.  Evaluation of Axillary Lymph Node Marking with Magseed® before and after Neoadjuvant Systemic Therapy in Breast Cancer Patients: MAGNET Study.

Authors:  María Martínez; Sara Jiménez; Florentina Guzmán; Marta Fernández; Elena Arizaga; Consuelo Sanz
Journal:  Breast J       Date:  2022-07-09       Impact factor: 2.269

Review 4.  The Evolving Role of Marked Lymph Node Biopsy (MLNB) and Targeted Axillary Dissection (TAD) after Neoadjuvant Chemotherapy (NACT) for Node-Positive Breast Cancer: Systematic Review and Pooled Analysis.

Authors:  Parinita K Swarnkar; Salim Tayeh; Michael J Michell; Kefah Mokbel
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639

Review 5.  Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study.

Authors:  Maggie Banys-Paluchowski; Maria Luisa Gasparri; Jana de Boniface; Oreste Gentilini; Elmar Stickeler; Steffi Hartmann; Marc Thill; Isabel T Rubio; Rosa Di Micco; Eduard-Alexandru Bonci; Laura Niinikoski; Michalis Kontos; Guldeniz Karadeniz Cakmak; Michael Hauptmann; Florentia Peintinger; David Pinto; Zoltan Matrai; Dawid Murawa; Geeta Kadayaprath; Lukas Dostalek; Helidon Nina; Petr Krivorotko; Jean-Marc Classe; Ellen Schlichting; Matilda Appelgren; Peter Paluchowski; Christine Solbach; Jens-Uwe Blohmer; Thorsten Kühn
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.